Key result
Myosin-inhibited fibroblasts transmit stiffness-dependent traction regulated by Arp2/3 and formin-assisted actin polymerization.
Why the study?
It was unclear whether extracellular matrix stiffness-dependent differential tension within integrin-based adhesions is induced solely by myosin activity.
Arp2/3 and formin enhance cellular stiffness sensitivity by mechanically reinforcing the F-actin network's viscoelasticity, enabling stiffness-dependent traction transmission even in the absence of myosin contractility.
Caution against clinical extrapolation; leaves open actin nucleators' role in cardiac fibroblast mechanosensing in vivo.
The stiffness of the extracellular matrix induces differential tension within integrin-based adhesions, triggering differential mechanoresponses. However, it has been unclear if the stiffness-dependent differential tension is induced solely by myosin activity. Here, we report that in the absence of myosin contractility, 3T3 fibroblasts still transmit stiffness-dependent differential levels of traction. This myosin-independent differential traction is regulated by polymerizing actin assisted by actin nucleators Arp2/3 and formin where formin has a stronger contribution than Arp2/3 to both traction and actin flow. Intriguingly, despite only slight changes in F-actin flow speed observed in cells with the combined inhibition of Arp2/3 and myosin compared to cells with sole myosin inhibition, they show a 4-times reduction in traction than cells with myosin-only inhibition. Our analyses indicate that traditional models based on rigid F-actin are inadequate for capturing such dramatic force reduction with similar actin flow. Instead, incorporating the F-actin network's viscoelastic properties is crucial. Our new model including the F-actin viscoelasticity reveals that Arp2/3 and formin enhance stiffness sensitivity by mechanically reinforcing the F-actin network, thereby facilitating more effective transmission of flow-induced forces. This model is validated by cell stiffness measurement with atomic force microscopy and experimental observation of model-predicted stiffness-dependent actin flow fluctuation.
No takes yet. Share an insight, caveat, or question.
Mittal et al. (2024) studied In vitro (NIH 3T3 fibroblasts). Myosin and actin polymerization inhibitors (Blebbistatin, CK666, SMIFH2, Latrunculin-A) vs. Wild-type (WT) control was evaluated on Traction force and F-actin retrograde flow speed in response to extracellular matrix stiffness. In the absence of myosin contractility, 3T3 fibroblasts transmit stiffness-dependent differential traction regulated by polymerizing actin assisted by Arp2/3 and formin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: